Tech Company M&A Transactions
Augmenix Acquisition
Augmenix was acquired by Boston Scientific. The transaction was announced on 9/7/2018. The transaction price was $600 million.
Transaction Overview
Company Name
Acquired By
Announced On
9/7/2018
Transaction Type
M&A
Amount
$600,000,000
M&A Terms
The transaction consists of an upfront cash payment of $500 million, and up to $100 million for reaching sales-based milestones.
Company Information
Company Status
Acquired or Merged
Industry
Medical Devices & Instruments
Mailing Address
204 2nd Ave. Lower Level
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Augmenix's hydrogel technology improves outcomes in prostate radiation oncology and surgery. Learn more about the SpaceOAR system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Pedersen
President
Pat Campbell
VP - Operations
Nick Svencer
VP - Regulatory Affairs
Noel Rolon
VP - Sales
Ken Knudson
Browse more venture capital transactions:
Prev: 9/7/2018: MIRROR venture capital transaction
Next: 9/7/2018: Twentyeight-Seven Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs